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Abstract
Background: Self-management is becoming essential for breast cancer survivors, but evidence about the
effectiveness of self-management support (SMS) intervention is lacking. To address this issue, we developed a
theory-based SMS intervention, the ‘EMPOWER’, aimed at empowering breast cancer survivors. Here we describe
the rationale of the intervention and its development.
Methods: The conceptual framework of this study is the Chronic Care Model, which posits that SMS can influence
patient-provider relationships and ultimately improve health outcomes. We will conduct a multi-center, 2-armed
randomized controlled trial to assess the effectiveness of EMPOWER among post-treatment breast cancer survivors
in South Korea. The trial will include 94 women who completed primary breast cancer treatment within the last 6
months. Participants will be randomly assigned to the intervention group or the wait-list control group (1:1). The
intervention group will receive a 7-week partnership-based and needs-tailored SMS intervention via telephone
counseling. The primary outcome is empowerment. The secondary outcomes include self-efficacy for post-
treatment self-management behaviors, mental adjustment, psychological distress, and health-related quality of life
(HRQOL). Data will be collected by self-reported questionnaire at baseline, post-intervention, and 3-month follow-
up.
Discussion: We believe that the EMPOWER intervention could improve HRQOL of post-treatment breast cancer
survivors by enhancing their empowerment. If found successful, it could aid clinicians engaged in the long-term
care of breast cancer survivors.
Trial registration: Clinical Research Information Service, KCT0004794. Registered 5 March 2020.
Keywords: Breast cancer, Randomized controlled trial, Self-management, Empowerment, Self-efficacy, Health-
related quality of life
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Background
Breast cancer is one of most common cancers among
women worldwide. Due to advances in early detection
and treatment, approximately 90% of women with breast
cancer survive at least 5 years after diagnosis [1]. At
some point after treatment, breast cancer may be con-
sidered a chronic illness [2].
Breast cancer survivors (BCS) face the numerous
health challenges that are associated with a complex
chronic condition, including managing persisting symp-
toms, identifying signs and symptoms of progression,
accessing needed information and support, and making
healthy lifestyle changes [3, 4]. Shouldering the responsi-
bility for self-management (SM) behaviors can help sur-
vivors live well [5]. Unfortunately, cancer survivors in
general report feelings of vulnerability and often lack the
confidence to initiate the actions required to recover
after their treatment [6]. This has led to increasing calls
for better SM enablement.
The Chronic Care Model (CCM) is one suggested
model for cancer survivorship care [7]. Introduced by
Wagner and colleagues [8] in 1998, it was designed to im-
prove the management and health outcomes of individuals
with chronic illnesses. In the CCM, the essential element
of good care is a productive interaction between informed,
motivated patients and a prepared practice team [8]. This
interaction can be influenced by 6 components of the
CCM [the health system, community resources, self-
management support (SMS), delivery system design, deci-
sion support, and clinical information systems]. Of those 6
components, SMS has been featured as a key component
for assuring quality healthcare [9].
SMS refers to support of an individual’s ability to manage
the symptoms, treatment, and physical, psychosocial, and
lifestyle changes inherent in living with a chronic condition
[8]. The application of SMS intervention among cancer sur-
vivors is increasing, and several BCS studies report its effi-
cacy for health outcomes [10–15]. Types of SMS
interventions are various and include distress management
[10], uncertainty management [11–13], coping [14], and
lifestyle management [15]. SMS interventions can signifi-
cantly improve cancer knowledge [12, 13], cognitive re-
framing [11–13], self-efficacy [10, 15], and health-related
quality of life (HRQOL) [15], and it can decrease psycho-
logical distress [10, 11]. Significance has not been demon-
strated, however, for SMS effects regarding empowerment
[10], patient-provider communication [11, 13], and social
support [12], thus rendering the full efficacy of SMS inter-
vention incomplete.
Managing everyday problems brought about by cancer
and/or its treatment is likely to be enhanced by a collab-
orative partnership between patients and health care
providers, all of whom are considered co-equal experts
of the condition, albeit from different perspectives [16].
Such a collaborative approach can delineate how health
care providers can support patients in their SM behav-
iors [6]. Given the importance of a productive inter-
action between patients and health care providers in
chronic care, an evaluation of relationship-related out-
comes such as empowerment is necessary.
In addition, the ‘one-size fits all’ approach for chronic
disease SM may not be adequate for a chronic illness as
complex as cancer. Several studies have shown that
current healthcare systems do not meet the survivors’
needs [17, 18]. Many experts suggest that an individual-
ized or tailored approach should be adopted in survivor-
ship care planning [19]. Because, to the best of our
knowledge, few studies have incorporated needs-tailored
SMS intervention among BCS, we developed EM-
POWER (PartnErship-based, tailored self-Management
support Program fOr Women with breast cancER)—a
partnership-based, needs-tailored SMS intervention for
BCS who completed their primary treatment. The goal
of EMPOWER is to enhance empowerment and increase
self-efficacy for SM behaviors, thereby improving health
outcomes among post-treatment BCS. This paper de-
scribes the design and methodological plan for a ran-
domized controlled trial (RCT) to evaluate the
effectiveness of EMPOWER in post-treatment BCS.
Hypotheses of the EMPOWER trial
The objective of this RCT is to test whether the EM-
POWER intervention is effective, compared with a con-
trol group, in improving health outcomes (mental
adjustment, psychological distress, and HRQOL) by en-
hancing empowerment and increasing self-efficacy for
SM behaviors among post-treatment BCS.
Methods/design
The EMPOWER trial’s study design and its intervention
are in in concordance with the guidelines of the Consoli-
dated Standards of Reporting Trials 2010 statement [20]
and the standard protocol Items: Recommendations for
Interventional Trials (SPIRIT) [21].
Study design
This study is a 2-armed RCT designed to test the effects
of EMPOWER vs a control intervention. A 7-week EM-
POWER intervention will be assessed at baseline (T0), 8
weeks (T1), and 20 weeks (T2). Figure 1 shows a flow
chart of the RCT; Fig. 2 shows the schedule of enroll-
ment, interventions, and assessments. The study will be
undertaken in South Korea’s two university hospitals—
Yonsei Medical Center and Inha University Hospital.
The Institutional Review Boards of both provided ethical
approval. Written informed consent will be obtained
from the participants.
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Participants of the study
Women will be eligible to participate if they 1) are aged
19 years or more, 2) were diagnosed histologically with
breast cancer, 3) were treated with a curative cancer
therapy (surgery, chemotherapy, or radiation therapy), 4)
completed a primary cancer treatment within the previ-
ous 6 months (except for anti-hormone therapy and tar-
geted therapy) 5) had two or more unmet needs in a
post-treatment screening test covering 12 items of un-
met needs concerning SM behaviors (i.e., follow-up visit,
pain management, fatigue management, insomnia man-
agement, lymphedema management, exercise, diet,
smoking cessation, alcohol consumption, stress manage-
ment, return to work, and sexual activity), and 6) are
able to use the telephone. Women will be excluded if
they had a recurrence, a metastasis, or another cancer.
Setting and procedure
Potential participants will be identified through
physician-referral and self-referral. Physicians (YU Cho,
S Park and MH Lee) will use electronic medical records
(EMRs) to screen them for eligibility criteria related to
diagnosis and treatment history and will tell potentially
eligible women about the study. The researcher (YH
Choe) will screen for more detailed eligibility criteria
among women who are interested in participating in the
study. Women who learned of our study through a flyer
and are interested in participating can contact the
Fig. 1 RCT flow chart. RCT, randomized controlled trial
Kim et al. BMC Cancer          (2020) 20:367 Page 3 of 9
researcher (YH Choe), who will screen them for eligibility
via a telephone interview and will review medical informa-
tion in the EMRs. Women who are finally eligible will
meet with the researcher, and all participants will meet in
the hospital and provide written informed consent.
Data will be collected via a self-reported questionnaire.
After randomization, participants will complete the base-
line assessment in a face-to-face interview. The researcher
will contact participants via telephone 8 and 20weeks
after baseline and encourage them to complete a follow-
up questionnaire via letter mail and send it back in an
enclosed pre-addressed and stamped return envelope.
Randomization
After the baseline assessment, we will use a computer-
generated block randomization procedure (block size 4,
6, 8) in a 1:1 allocation ratio to randomize participants
to either the EMPOWER group or the control group.
Group assignments will be placed in sealed, sequentially
numbered envelopes and opened by the participants.
The recruiter will thereby be blinded to the study arm
assignments of the participants. Because of the social na-
ture of the intervention, however, participants cannot be
blinded to the study arm assignments.
Study groups
The EMPOWER intervention group
Based on the CCM, EMPOWER involves provider-
participant partnerships. Such partnerships that help
participants play a larger role in managing their post-
treatment medical problems, thereby helping them reach
their care goals [7]. SMS empowerment can extend to
late and long-term treatment effects as well, helping sur-
vivors understand when to seek support and encour-
aging healthy lifestyle changes [6].
Participants in the EMPOWER group will receive a 7-
week partnership-based, needs-tailored SMS interven-
tion via telephone counseling (ten 15- to 20-min ses-
sions, totaling 175min). We extracted the intervention
program contents from the conceptual SM framework in
chronic illness [22], the qualitative data from a Korean
BCS focus group interview regarding post-treatment SM
needs [23] structured by 5 SM tasks (medical manage-
ment, symptom management, lifestyle management,
emotional management, and role management) and 21
specific topics (Table 1). An expert advisory team (3 sur-
geons, 1 advanced practice nurse, and 1 nursing profes-
sor) validated the final thematic structure.
The EMPOWER intervention is subdivided into a 3-
week SM education part and a 4-week SM skill training
part (Table 2). At the end of the education part, partici-
pants will receive SM skill training in the topic of their
choice. Currently, we have modules for the 6 topics
(pain, fatigue, insomnia, exercise, diet, and distress) we
have accumulated evidence for the intervention.
Through participant choice, providers can tailor SM skill
training to individual needs.
Fig. 2 SPIRIT schedule of enrollment, interventions and assessment. HRQOL, health-related quality of life
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Using a 96-page evidence- and theory-based work-
book, master-level nurses will deliver the SM education
and skill training by telephone. The education and ac-
tion planning contents of the workbook were extracted
from the Korean National Cancer Information Center
[24], the National Comprehensive Cancer Network [25],
and the Oncology Nursing Society [26]. During the edu-
cation sessions, providers will exploit Badura’s self-
efficacy sources [27], such as verbal persuasion, vicarious
experience, mastery, and physiological states. The work-
book, for example, includes various vicarious experi-
ences leading, for example, to success in weight
management, exercise performance, and work resump-
tion. During the SM skill training sessions, providers will
present Lorig and Holman’s SM skills of problem solv-
ing, decision-making, taking action, forming partner-
ships, and utilizing resources [22]. The training uses a
structured module according to a weekly plan (Table 3).
Table 1 Thematic structure and contents of the EMPOWER intervention
SM task SM education topic SM skill training
Medical management Follow-up after treatment
Late/long-term effects
Sign and symptoms of recurrence
Second cancer screening
Vaccination
Side effects of anti-hormone therapy (if applicable)










Emotional management Distress √
Role management Body image
Sexuality (if applicable)
Return to work (if applicable)
Recovery of self-confidence
SM self-management
Table 2 Delivery of the EMPOWER intervention
Week Session no. Topic Telephone time (min.)
1 1 SM education: Medical management 20
2 SM education: Symptom management 20
2 3 SM education: Lifestyle management 20
4 SM education: Emotional management 20
3 5 SM education: Role management 20
6 1st SM skill training: Selected own topic 15
4 7 2nd SM skill training: Selected own topic 15
5 8 3rd SM skill training: Selected own topic 15
6 9 4th SM skill training: Selected own topic 15
7 10 Discussion: Healthy future plan 15
Total 175
Kim et al. BMC Cancer          (2020) 20:367 Page 5 of 9
The participant workbook is composed of a structured for-
mat that includes problem identification, goal setting, action
planning, resource identification, and action monitoring. Fa-
cilitation of provider-participant partnerships is provided by
a telephone counseling module that uses motivational inter-
viewing principles (i.e., open questions, affirmation, reflective
listening, and summary reflections) [28].
The control group
Participants in the control group will receive a 51-page edu-
cation book whose content is the same as Part 1 of the
intervention workbook. It includes SM strategies after can-
cer treatment but excludes SM skill training. At the end of
the study, the control group can request the intervention.
Study outcomes
The overview of the psychometric properties of primary
and secondary outcome measures is presented in
Table 4.
Primary outcome
We will evaluate empowerment using the Empowerment
Scale for Women with Breast Cancer [29]—a 30-item
self-report instrument consisting of intrapersonal factors
(14 items), interactional factors (8 items), and behavioral
factors (8 items). Scored on a 5-point Likert scale, a high
score indicates higher empowerment. The scale has
shown good validity and reliability [29].
Secondary outcomes
We will measure self-efficacy for SM among BCS using
a Korean version of the Cancer Survivors’ Self-Efficacy
Scale (CSSES-K) [30]. The original version of CSSES is
an 11-item questionnaire assessing cancer survivors’
cancer-related self-efficacy [31]. The CSSES-K is a 10-
item, 2-factor questionnaire. The factors are ‘self-efficacy
for managing health problems’ (5 items) and ‘self-effi-
cacy for seeking help and support’ (5 items) [30]. Each
item is rated on a 10-point scale from 1 (not at all
Table 3 Weekly contents of 6 self-management skill training modules
Module Goal Week 1 Week 2 Week 3 Week 4 Week 5
Pain Able to verbally express
own pain and practice
according to pain Mx plan.
Weekly goal:
Understand the pattern
of pain (severity, location,
quality, duration, etc.).
Action plan:
Making a pain diary
Weekly goal:
Learn ways of pain
Mx based on each
pain type.
Action plan:
















Fatigue Able to identify the cause
of own fatigue and practice
according to fatigue Mx plan.
Weekly goal:

























Insomnia Able to identify pattern






Making a sleep diary.
Weekly goal:
Learn ways of insomnia
Mx (stimulation control).
Action plan:
















Exercise Able to establish
individualized exercise
goal and practice
according to exercise plan.
Weekly goal:

























Diet Able to establish
individualized diet
goal and practice

























Distress Able to identify types












































Mx management, NCCN National Comprehensive Cancer Network
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confident) to 10 (totally confident); a higher score indi-
cates higher self-efficacy. The original version of CSSES
has a good reliability and validity [31], thus the CSSES-K
has adequate internal consistency (Cronbach’s alpha =
0.86–0.92) [30].
We will evaluate mental adjustment using a Korean
version of Mini-Mental Adjustment to Cancer (Mini-
MAC) [32]. The original Mini-MAC is a 29-item self-
rating questionnaire and includes 5 factors: 4 for Fight-
ing Spirit (FS), 8 for Help-Hopeless (HH), 8 for Anxious
Preoccupation (AP), 5 for Fatalism (FA), and 4 for Cog-
nitive Avoidance (CA) [33]. The Korean version of Mini-
MAC uses a 4-point Likert scale and includes 4 fac-
tors—8 items for HH, 8 for AP, 4 for CA, and 9 for Posi-
tive Attitude (PA). The Cronbach’s alpha coefficients of
the Korean version of Mini-MAC are 0.50–0.86, and
test-retest coefficients are 0.68–0.88 [32].
Anxiety and depression will be assessed using the Hos-
pital Anxiety and Depression Scale (HADS) [34]. HADS
is a 14-item self-report instrument assessing symptoms
of anxiety and depression that reflects 2 subscales, with
7 items for depression and 7 items for anxiety. Each item
is scored from 0 to 3, with higher scores indicating more
distress. The Korean HADS has been validated and has
shown good validity and reliability [35].
We will measure HRQOL using the 36-item Short-
Form Health Survey (SF-36) [36]—a 36-item question-
naire that consists of 2 domains (physical and mental)
and 8 subscales (functioning, physical role functioning,
bodily pain, general health, vitality, social role function-
ing, emotional role functioning, and mental health). Each
subscale is scored from 0 to 100, with higher scores indi-
cating better functioning and well-being. The SF-36 has
been translated into Korean and shown good validity
and reliability [37].
Sample size calculation
Based on the primary outcome ‘empowerment’, at least
78 patients will be required using an effect size of 0.65
[38], a power of 0.8, and an alpha less than 0.05. Assum-
ing an estimated dropout of 20%, 47 participants will be
needed in each group (a total of 94 participants).
Statistical analysis
We will describe the characteristics of the study partici-
pants using frequency and percentage for categorical
variables and means and standard deviations for
Table 4 EMPOWER study outcomes





30 items and 3 factors. Factors include ‘intrapersonal
factor’ (14 items), ‘interactional factor’ (8 items), and
‘behavioral factor’ (8 items). 5-point Likert scale. High
score indicates higher empowerment.
Goodness of fit of the final research model was very
appropriate as shown by χ2/df = 1.86, TLI = 0.90, CFI =
0.92, SRMR = 0.06, and RMSEA = 0.05. Criterion validity
was evaluated by total correlation with the Cancer
Empowerment Questionnaire 0.78. Cronbach’s alpha







10 items and 2 factors. Factors include ‘Self-efficacy
for managing health problems’ (5 items) and ‘self-
efficacy for seeking help and support’ (5 items). 10-
point Likert scale. Higher score indicates higher self-
efficacy.
Construct validity was evaluated with general self-
efficacy (0.511), anxiety (−0.596), depression (− 0.554)
and health-related quality of life (0.586). Cronbach’s






29 item and 4 factors. Factors include Helpless-
Hopeless (HH), Anxious Preoccupation (AP) Positive
Attitude (PA), Cognitive Avoidance (CA), and Fighting
Spirit (FS).
Construct validity was evaluated with each of anxiety
and depression subscales of HADS, AP (0.63, and 0.58),
HH (0.54, and 0.59), FS (−0.30, and − 0.37), and PA (−
0.19, and − 0.23). Cronbach’s alpha was 0.50–0.86 and





14 item and 2 subscales. Subscales are ‘an anxiety
(HADS-A)’ and ‘a depression (HADS-D)’.
4-point Likert scale. Higher score indicates greater
anxiety or depression.
Construct validity of HADS-D was evaluated with Beck
Depression Inventory 0.80, and HADS-A with Self-
Rating Anxiety Scale was 0.79. Items of the HADS-A
and corrected item total score was 0.55 and HADS-D




36 items, 8 subscales and 2 domains. Domains
include ‘physical component’ and ‘mental
component’. Each subscale is scored 0 to 100. Higher
score indicates better functioning and well-being.
The SF-36 has been validated in South Korea. Cron
bach’s alpha was 0.89 for physical component, 0.87
for mental component, and 0.93 for total score [37].
CFI comparative fit index, HRQOL health-related quality of life, RMSEA root mean square error of approximation, SRMR standardized root mean square residual, TLI
Tucker-Lewis Index
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continuous variables. To compare baseline characteris-
tics between the two groups, we will use independent t-
tests for normally distributed continuous variables, the
Mann-Whitney test for non-parametric variables, and
the chi square test for categorical variables. We will use
linear mixed models to analyze the efficacy of EM-
POWER and Cohen’s d to estimate effect size as large
(≥0.80), moderate (0.5–0.79), or small (< 0.50) [39].
Missing data will be handled under the missing-at-
random assumption. We will perform all analyses using
IBM SPSS Statistics version 25.0 (IBM, Armonk, NY,
USA) according to the intention-to-treat principle and
consider a p-value < 0.05 significant.
Discussion
We developed the EMPOWER intervention with the
intention of improving health outcomes by enhancing
empowerment and increasing self-efficacy in post-
treatment BCS, thus facilitating successful transition
from hospital-based survivorship care to SMS care. Ex-
pected outcomes include decreased psychological dis-
tress, better mental adjustment, and improved HRQOL.
If successful, this study will provide evidence that SMS
may be an important survivorship care model.
EMPOWER has several strengths. First, it is theory-
based; we applied self-efficacy theory [27], Lorig and
Holman’s model [22], and motivational interviewing
technique [28] for development and delivery of the inter-
vention. EMPOWER’s main mechanism will be to facili-
tate partnership between provider and participant and
increase self-efficacy of the participant. Second, EM-
POWER is needs-tailored. Although substantial BCS
have unmet needs after cancer treatment [40, 41], there
is a lack of interventions that meet their supportive care
needs in a personalized manner. We believe that EM-
POWER’s Part 2 intervention (4-week SM skill training
for participant’s chosen topic) will work as a needs-
based tailored intervention. Third, EMPOWER’s SM
skill training protocol is evidence-based. We developed
action-planning protocols for each SM topic based on
interventions that were already proven effective.
EMPOWER has also several weaknesses. First, it can
be resource intensive because it is delivered by a well-
trained nurse via telephone. That burden could be re-
duced, however, by delivering the Part 1 intervention
(SM education) by an app or on the web. Second, SM
skill training is available for only 6 topics (management
of pain, fatigue, insomnia, distress, exercise, and diet).
As more evidence becomes available, other SM topics
could be developed. Third, generalization to a wider set-
ting and in other countries must be done with caution
because the prioritized SM topics were chosen by the
Korean population.
Conclusion
EMPOWER is a theory-based SMS intervention unique
in its provider-partnership and needs-tailored approach.
If found successful, the EMPOWER trial will offer in-
sights into how clinicians can engage in chronic care for
BCS after treatment using SMS intervention.
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